Overview

  • Product name
    Anti-Osteoprotegerin antibody [OPG 01]
    See all Osteoprotegerin primary antibodies
  • Description
    Mouse monoclonal [OPG 01] to Osteoprotegerin
  • Tested applications
    Suitable for: ELISA, WBmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Recombinant human osteoprotegerin (OPG Fc Chimera)(Human).

  • General notes

    Abcam is committed to meeting high standards of ethical manufacturing and as such, we will be discontinuing this product, which has been generated by the ascites method, within the next year. We are sorry for any inconvenience this may cause. If you would like help finding an alternative product, please do not hesitate to contact our scientific support team.

Properties

Applications

Our Abpromise guarantee covers the use of ab14049 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ELISA Use at an assay dependent dilution.
WB Use at an assay dependent dilution. Predicted molecular weight: 48 kDa.

Target

  • Function
    Acts as decoy receptor for RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local RANKL/OPG ratio. May also play a role in preventing arterial calcification. May act as decoy receptor for TRAIL and protect against apoptosis. TRAIL binding blocks the inhibition of osteoclastogenesis.
  • Tissue specificity
    Highly expressed in adult lung, heart, kidney, liver, spleen, thymus, prostate, ovary, small intestine, thyroid, lymph node, trachea, adrenal gland, testis, and bone marrow. Detected at very low levels in brain, placenta and skeletal muscle. Highly expressed in fetal kidney, liver and lung.
  • Involvement in disease
    Defects in TNFRSF11B are the cause of juvenile Paget disease (JPD) [MIM:239000]; also known as hyperostosis corticalis deformans juvenilis or hereditary hyperphosphatasia or chronic congenital idiopathic hyperphosphatasia. JPD is a rare autosomal recessive osteopathy that presents in infancy or early childhood. The disorder is characterized by rapidly remodeling woven bone, osteopenia, debilitating fractures, and deformities due to a markedly accelerated rate of bone remodeling throughout the skeleton. Approximately 40 cases of JPD have been reported worldwide. Unless it is treated with drugs that block osteoclast-mediated skeletal resorption, the disease can be fatal.
  • Sequence similarities
    Contains 2 death domains.
    Contains 4 TNFR-Cys repeats.
  • Post-translational
    modifications
    N-glycosylated. Contains sialic acid residues.
    The N-terminus is blocked.
  • Cellular localization
    Secreted.
  • Information by UniProt
  • Database links
  • Alternative names
    • MGC29565 antibody
    • OCIF antibody
    • OPG antibody
    • Osteoclastogenesis inhibitory factor antibody
    • Osteoprotegerin antibody
    • PDB5 antibody
    • TNF receptor superfamily member 11b antibody
    • TNFRSF 11B antibody
    • TNFRSF11B antibody
    • TR 1 antibody
    • TR1 antibody
    • TR11B_HUMAN antibody
    • Tumor necrosis factor receptor superfamily member 11B antibody
    see all

References for Anti-Osteoprotegerin antibody [OPG 01] (ab14049)

This product has been referenced in:
  • Pitari MR  et al. Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts. Oncotarget 6:27343-58 (2015). WB . Read more (PubMed: 26160841) »

See 1 Publication for this product

Product Wall

There are currently no Abreviews or Questions for ab14049.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up